| Author, year | Sample size |
Intervention methods | Duration | Outcomes | EG | CG | EG | CG | (wks) |
| Lao 2000 [8] | 32 | 32 | ZQFTN 20–40 mg tid, MTX 7.5 mg qw | MTX 15 mg qw | 12 | TE, TJC, SJC, DMS, RF, ESR, AE |
| Wu 2003 [9] | 40 | 40 | ZQFTN 40 mg tid, MTX 7.5 mg qw | MTX 15 mg qw | 12 | TE, TJC, SJC, DMS, RF, ESR, AE |
|
Sun and Lan 2006 [10] | 62 | 58 | ZQFTN 120 mg qd, MTX 15 mg qw | MTX 15 mg qw | 24 | TE, RF, ESR, CRP, AE |
| Ji and Zhu 2006 [11] | 30 | 30 | ZQFTN 20–40 mg tid, MTX 7.5 mg qw | MTX 15 mg qw | 12 | TE, TJC, SJC, DMS, RF, ESR, CRP, AE |
| Ding 2010 [12] | 31 | 31 | ZQFTN 20–40 mg tid, MTX 7.5 mg qw | MTX 15 mg qw | 12 | TE |
| Huang and Wang 2010 [13] | 30 | 30 | ZQFTN 60 mg bid, MTX 7.5 mg qw | MTX 15 mg qw | 12 | TE, TJC, SJC, DMS, RF, ESR, CRP, AE |
| Xia et al. 2012 [14] | 52 | 52 | ZQFTN 60 mg tid, MTX 10 mg qw | MTX 10 mg qw | 12 | TE, TJC, SJC, DMS, RF, ESR, CRP, AE |
| Zhu et al. 2013 [15] | 36 | 36 | ZQFTN 60 mg bid, MTX 10 mg qw | MTX 10 mg qw | 24 | TE, TJC, SJC, DMS, ESR, CRP, AE |
| Li et al. 2008 [16] | 35 | 34 | ZQFTN 120 mg bid, MTX 10 mg qw | MTX 15 mg qw | 8 | TE, DMS, RF, ESR, CRP, AE |
| Wang 2010 [17] | 120 | 66 | ZQFTN 120 mg bid, MTX 10 mg qw | MTX 10 mg qw | 24 | TE, DMS, RF, ESR, CRP, AE |
| Lu and Su 2011 [18] | 40 | 39 | ZQFTN 120 mg bid, MTX 10 mg qw | MTX 10 mg qw | 12 | TE, TJC, RF, ESR, CRP, AE |
|
|